Replies to post #323485 on NorthWest Biotherapeutics Inc (NWBO)

[abeta]

Alex

I did not read the article - it is "OUT THERE".
So I posted it.

Put me on ignore and move on.

The trial didn´t stop because for superior efficacy because of the unexpected high number of patients crossing over from placebo to dcvax-l. And because the primary endpoint was PFS, it was too hard to determine PFS/pseudo PFS. that´s the only reason.
So only the bullish case remains. Do your dd.

[abc1212]

Good point alexander77

Did you also notice how the report only had 7 lines of text under the Bullish heading but had 27 lines of text under the Bearish heading which was more or less about Optune & Novocure than DCVax

Then look to bottom of report in disclosures and it mentions
'The Motley Fool owns shares of and recommends Novocure.'

Well there's a surprise.


Anyone who would seriously be guided by any Motley Fool biased reports is nothing but a fool themselves.